What is Foundayo?

What kind of medicine is it?

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. It acts on the same receptor family as semaglutide but is a different molecule. It should not be described as oral Mounjaro: Mounjaro contains tirzepatide and has a different receptor profile. [2][3]

The UK Foundayo product information includes adult weight management and treatment of insufficiently controlled type 2 diabetes. [1] A clinician must assess the indication and suitability.

When reading about this medicine, check the country as well as the date. A US launch announcement or a European committee opinion does not set UK prescribing instructions. For the medicine dispensed in the UK, start with the UK leaflet and prescribing information linked below.

What taking it involves

The patient leaflet describes once-daily use at any time of day, with or without food. Tablets should be swallowed whole, not broken, crushed or chewed, and no more than one tablet should be taken per day. This differs from the fasting routine for oral Wegovy. [4][5]

UK film-coated strengths are 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. [4] A list of strengths is not a schedule to work through without review.

Discuss what will make a daily routine workable: a reliable reminder, repeat-prescription arrangements and a clear way to ask about missed treatment. A tablet may suit someone's preferences, but convenience should be considered alongside safety, benefit and the rest of their medicines.

Why a trial may mention 36 mg

ATTAIN-1 reported investigational capsule doses of 6, 12 and 36 mg. The UK product information explains differences between the trial capsules and marketed film-coated tablets; for example, the 36 mg capsule corresponds to the 17.2 mg tablet formulation. [1][2] Do not interpret “36 mg” as a UK tablet prescription or calculate a replacement by adding tablets.

This distinction matters when comparing claims. Copy the formulation as well as the number into your notes. If an article omits whether the dose refers to capsules or tablets, use the original trial and current UK product information to resolve it before drawing conclusions.

What the research can and cannot show

ATTAIN-1 followed adults with obesity, or overweight with a complication, without diabetes for 72 weeks. Orforglipron produced more weight reduction than placebo with diet and activity support. Gastrointestinal effects were the most frequent adverse events; between 5.3% and 10.3% stopped treatment because of adverse events in the orforglipron groups, versus 2.7% with placebo. [2]

The trial supports efficacy against placebo. It does not establish a universal ranking against current injectable treatments or oral semaglutide. A result also depends on how treatment discontinuation and missing measurements were handled, which is why a single percentage can be misleading without its analysis method.

A later ATTAIN-1 analysis estimated changes in predicted ten-year diabetes and cardiovascular risk using risk calculators. Those modelled changes are not the same as observing fewer heart attacks, strokes or new diabetes diagnoses over ten years. [6]

ATTAIN-MAINTAIN investigated oral treatment after prior injectable weight reduction. Its limitations included one-year follow-up and no group continuing the injectable treatment, so it cannot show that switching is as effective as staying on an injection. [7]

Medicine checks remain essential

The leaflet discusses digestive side effects and circumstances requiring medical advice. It also addresses glucose testing when Foundayo is used with insulin or a sulfonylurea. Tell the clinician about every prescription, non-prescription medicine and supplement. [4]

The UK prescribing information identifies an interaction with simvastatin requiring a clinician-managed dose change. This is one reason a general statement that a tablet is “easy to take” is not enough to establish suitability. Do not change a cholesterol medicine yourself. [1]

Before starting, ask the service to explain urgent symptoms, pregnancy and breastfeeding advice, and whom to contact outside routine appointments. If instructions conflict with something read about another GLP-1 medicine, ask the pharmacist to check the Foundayo-specific information.

Avoid Foundayo in pregnancy or breastfeeding. Its leaflet gives a three-week interval before planned pregnancy and advises considering barrier or non-oral contraception for 30 days after starting and each increase when using oral hormonal contraception. [4] Discuss the method and timing with a clinician.

How to discuss access without assuming it

The authorisation establishes that a UK product licence exists. It does not confirm that a particular pharmacy has stock, that your NHS service funds treatment or that a quoted introductory price will apply later.

Ask for the full product name, the indication being considered, the follow-up arrangements and the complete expected costs before agreeing to private care. Use a registered pharmacy and a proper prescribing consultation. Avoid sellers presenting “research” products as a substitute for a licensed medicine. [8][9]

Questions and answers